Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  ovarian serous cystadenocarcinoma
Stage/Subtype:  ovarian serous cystadenocarcinoma
Country:  U.S.A.
Trial Type:  Treatment
Results 1-25 of 28 for your search:
Start Over
Trametinib in Treating Patients with Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer
Status: Active
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 19 and over
Trial IDs: GOG-0281, NCI-2014-00629, NCT02101788
Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients with Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Active
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NRG-GY005, NCI-2015-00651, NCT02502266
Pegylated Liposomal Doxorubicin Hydrochloride with Atezolizumab and/or Bevacizumab in Treating Patients with Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Not yet active
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NRG-GY009, NCI-2016-01081, NCT02839707
MV-NIS Infected Mesenchymal Stem Cells in Treating Patients with Recurrent Ovarian Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MC1266, NCI-2014-00016, NCT02068794
Phase 1/2a Evaluation of AL3818 in Subjects With Recurrent or Metastatic Endometrial, Ovarian or Cervical Cancer (AL3818-US-001)
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: AL3818-US-001, NCI-2015-01926, NCT02558348
Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Triple-negative Breast Cancer or Ovarian Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 3000-PN162-01-001, NCI-2016-00219, NCT02657889
Olaparib and Tremelimumab in Treating BRCA1 or BRCA2 Mutation Carrier Patients with Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 99
Trial IDs: INST 1419, NCI-2016-00434, NCT02571725
Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients with Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NRG-GY007, NCI-2016-00203, NCT02713386
Cyclodextrin-Based Polymer-Camptothecin CRLX101 with or without Bevacizumab in Treating Patients with Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
Status: Temporarily closed
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 19 and over
Trial IDs: 11-485, NCI-2012-01544, NCT01652079
Nintedanib in Treating Patients with Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Previously Treated with Bevacizumab
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: Pro00033060, NCI-2013-00455, NCT01669798
Surgery with or without Carboplatin in Treating Patients with Recurrent Ovarian, Primary Peritoneal Cavity, or Fallopian Tube Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: Over 21
Trial IDs: 12-275, NCI-2013-00405, NCT01767675
Enzalutamide in Treating Patients with Advanced or Recurrent Androgen Receptor-Positive Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-119, NCI-2013-02217, NCT01974765
Gemcitabine Hydrochloride with or without WEE1 Inhibitor MK-1775 in Treating Patients with Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: PHL-093, NCI-2014-00620, NCI 9568, NCT02151292, 9568, NCT02101775
Metformin Hydrochloride and Combination Chemotherapy in Treating Patients with Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 77
Trial IDs: IRB13-1235, NCI-2014-00860, UC IRB13-1235, NCT02122185
LY2606368 in Treating Patients with BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple-Negative Breast Cancer, High Grade Ovarian Cancer, or Metastatic Hormone-Resistant Prostate Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 14-C-0156, NCI-2014-02304, 140156, 342996, P131428, NCT02203513
Olaparib and Cediranib Maleate in Treating Patients with Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9825, NCI-2015-00051, PENDING, NCT02345265
MV-NIS or Investigator's Choice Chemotherapy in Treating Patients with Ovarian, Fallopian, or Peritoneal Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MC1365, NCI-2015-00133, NCT02364713
Effect of Acetylcysteine with Topotecan Hydrochloride on the Tumor Microenvironment in Patients with Persistent or Recurrent High Grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15P.404, NCI-2015-01564, 2015-005, 2405, JeffTrial 7408, NCT02569957
Buparlisib or Alpelisib and Olaparib in Treating Patients with Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-159, NCI-2012-01929, CBKM120ZUS32T, ISS22810064, NCT01623349
A Study of Atezolizumab Administered in Combination With Bevacizumab and/or With Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GP28328, NCI-2013-00509, 2012-001422-10, NCT01633970
Cisplatin, Paclitaxel, Bevacizumab, and Olaparib in Treating Patients with Newly Diagnosed Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Have Undergone Initial Surgery
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 10-220, NCI-2014-01020, NCT02121990
TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients with Recurrent Glioblastoma or Advanced Solid Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 14-079, NCI-2014-01118, 9552, NCT02142803
Genetically Modified T Cells with or without Cyclophosphamide in Treating Patients with Recurrent Mesothelin-Expressing Cancers That Cannot Be Removed by Surgery
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: UPCC 31213, NCI-2015-00392, 819826, NCT02159716
Start Over